PRDM1 and neoplasm: Finally, for clinical applications, it is important to recognize that if elimination of the PRDM1/NR4A3 double-edited cells is compromised, a situation whereby a very large number of T-cells accumulate that are marginally less effective at tumor cell killing may considerably increase the risk of toxicity.